Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuki Ando

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Frontiers in Allergy|October 9, 2025
Correction: Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: trelegy ellipta for real asthma control studyYoshitomo Kushima, Yasuo Shimizu, Ryo Arai, et al.
Journal of Gastroenterology|April 20, 2026
Novel driver gene FIRRM regulates the cell cycle for promoting tumor growth in hepatocellular carcinomaTomohiko Ikehara, Hajime Otsu, Taro Tobo, et al.
Scientific Reports|March 3, 2026
Multicenter ex vivo evaluation of an α-mannosidase-targeted fluorescent probe for intraoperative margin assessment in breast cancerHiroki Ueo, Hiroaki Ueo, Takako Doi, et al.
Cancer Science|March 18, 2024
Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancerMasahiro Hashimoto, Takaaki Masuda, Yusuke Nakano, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 14, 2026
Identification of the Inflammatory Cytokine Tumor Necrosis Factor Superfamily 4 as an Oncogenic Driver and Potential Druggable Target in Hepatocellular CarcinomaKiyotaka Hosoda, Takaaki Masuda, Hideyuki Saito, et al.
Cancer Science|June 30, 2026
NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2Tomohiko Ikehara, Hajime Otsu, Taro Tobo, et al.
BMC Medicine|November 17, 2018
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive designMunyaradzi Dimairo, Elizabeth Coates, Philip Pallmann, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
BMJ (Clinical Research Ed.)|June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Cancer Science|October 22, 2025
ZNF282 Promotes Colorectal Cancer Progression Possibly via E2F1 ActivationTadashi Abe, Takaaki Masuda, Taro Tobo, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Frontiers in Allergy|October 9, 2025
Correction: Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: trelegy ellipta for real asthma control studyYoshitomo Kushima, Yasuo Shimizu, Ryo Arai, et al.
Journal of Gastroenterology|April 20, 2026
Novel driver gene FIRRM regulates the cell cycle for promoting tumor growth in hepatocellular carcinomaTomohiko Ikehara, Hajime Otsu, Taro Tobo, et al.
Scientific Reports|March 3, 2026
Multicenter ex vivo evaluation of an α-mannosidase-targeted fluorescent probe for intraoperative margin assessment in breast cancerHiroki Ueo, Hiroaki Ueo, Takako Doi, et al.
Cancer Science|March 18, 2024
Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancerMasahiro Hashimoto, Takaaki Masuda, Yusuke Nakano, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 14, 2026
Identification of the Inflammatory Cytokine Tumor Necrosis Factor Superfamily 4 as an Oncogenic Driver and Potential Druggable Target in Hepatocellular CarcinomaKiyotaka Hosoda, Takaaki Masuda, Hideyuki Saito, et al.
Cancer Science|June 30, 2026
NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2Tomohiko Ikehara, Hajime Otsu, Taro Tobo, et al.
BMC Medicine|November 17, 2018
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive designMunyaradzi Dimairo, Elizabeth Coates, Philip Pallmann, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
BMJ (Clinical Research Ed.)|June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Cancer Science|October 22, 2025
ZNF282 Promotes Colorectal Cancer Progression Possibly via E2F1 ActivationTadashi Abe, Takaaki Masuda, Taro Tobo, et al.
Pageof 7